Rare Germline Genetic Variants and the Risks of Epithelial Ovarian Cancer
- PMID: 33086730
- PMCID: PMC7589980
- DOI: 10.3390/cancers12103046
Rare Germline Genetic Variants and the Risks of Epithelial Ovarian Cancer
Abstract
A family history of ovarian or breast cancer is the strongest risk factor for epithelial ovarian cancer (EOC). Germline deleterious variants in the BRCA1 and BRCA2 genes confer EOC risks by age 80, of 44% and 17% respectively. The mismatch repair genes, particularly MSH2 and MSH6, are also EOC susceptibility genes. Several other DNA repair genes, BRIP1, RAD51C, RAD51D, and PALB2, have been identified as moderate risk EOC genes. EOC has five main histotypes; high-grade serous (HGS), low-grade serous (LGS), clear cell (CCC), endometrioid (END), and mucinous (MUC). This review examines the current understanding of the contribution of rare genetic variants to EOC, focussing on providing frequency data for each histotype. We provide an overview of frequency and risk for pathogenic variants in the known susceptibility genes as well as other proposed genes. We also describe the progress to-date to understand the role of missense variants and the different breast and ovarian cancer risks for each gene. Identification of susceptibility genes have clinical impact by reducing disease-associated mortality through improving risk prediction, with the possibility of prevention strategies, and developing new targeted treatments and these clinical implications are also discussed.
Keywords: ovarian cancer risk; rare germline variants; susceptibility genes.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Genetic epidemiology of ovarian cancer and prospects for polygenic risk prediction.Gynecol Oncol. 2017 Dec;147(3):705-713. doi: 10.1016/j.ygyno.2017.10.001. Epub 2017 Oct 18. Gynecol Oncol. 2017. PMID: 29054568 Review.
-
Exome sequencing identifies HELB as a novel susceptibility gene for non-mucinous, non-high-grade-serous epithelial ovarian cancer.medRxiv [Preprint]. 2024 Apr 3:2024.04.02.24304968. doi: 10.1101/2024.04.02.24304968. medRxiv. 2024. Update in: Eur J Hum Genet. 2025 Mar;33(3):297-303. doi: 10.1038/s41431-025-01786-0. PMID: 38633804 Free PMC article. Updated. Preprint.
-
Exome sequencing identifies HELB as a novel susceptibility gene for non-mucinous, non-high-grade-serous epithelial ovarian cancer.Eur J Hum Genet. 2025 Mar;33(3):297-303. doi: 10.1038/s41431-025-01786-0. Epub 2025 Feb 12. Eur J Hum Genet. 2025. PMID: 39939714 Free PMC article.
-
Enhancing the BOADICEA cancer risk prediction model to incorporate new data on RAD51C, RAD51D, BARD1 updates to tumour pathology and cancer incidence.J Med Genet. 2022 Dec;59(12):1206-1218. doi: 10.1136/jmedgenet-2022-108471. Epub 2022 Sep 26. J Med Genet. 2022. PMID: 36162851 Free PMC article.
-
Moderate-Risk Genes for Hereditary Ovarian Cancers Involved in the Homologous Recombination Repair Pathway.Int J Mol Sci. 2022 Oct 4;23(19):11790. doi: 10.3390/ijms231911790. Int J Mol Sci. 2022. PMID: 36233090 Free PMC article. Review.
Cited by
-
Validation of the BOADICEA model for epithelial tubo-ovarian cancer risk prediction in UK Biobank.Br J Cancer. 2024 Nov;131(9):1473-1479. doi: 10.1038/s41416-024-02851-z. Epub 2024 Sep 18. Br J Cancer. 2024. PMID: 39294438 Free PMC article.
-
Germline RAD51C and RAD51D Mutations in High-Risk Chinese Breast and/or Ovarian Cancer Patients and Families.J Pers Med. 2024 Aug 16;14(8):866. doi: 10.3390/jpm14080866. J Pers Med. 2024. PMID: 39202057 Free PMC article.
-
Case Review: Whole-Exome Sequencing Analyses Identify Carriers of a Known Likely Pathogenic Intronic BRCA1 Variant in Ovarian Cancer Cases Clinically Negative for Pathogenic BRCA1 and BRCA2 Variants.Genes (Basel). 2022 Apr 15;13(4):697. doi: 10.3390/genes13040697. Genes (Basel). 2022. PMID: 35456503 Free PMC article.
-
Germline Mutations in 12 Genes and Risk of Ovarian Cancer in Three Population-Based Cohorts.Cancer Epidemiol Biomarkers Prev. 2023 Oct 2;32(10):1402-1410. doi: 10.1158/1055-9965.EPI-23-0041. Cancer Epidemiol Biomarkers Prev. 2023. PMID: 37493628 Free PMC article.
-
Risk-reducing salpingectomy with delayed oophorectomy to prevent ovarian cancer in women with an increased inherited risk: insights into an alternative strategy.Fam Cancer. 2024 Nov;23(4):437-445. doi: 10.1007/s10689-024-00412-0. Epub 2024 Jun 21. Fam Cancer. 2024. PMID: 38907139 Free PMC article. Review.
References
-
- Buys S.S., Partridge E., Black A., Johnson C.C., Lamerato L., Isaacs C., Reding D.J., Greenlee R.T., Yokochi L.A., Kessel B., et al. Effect of screening on ovarian cancer mortality: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011;305:2295–2303. doi: 10.1001/jama.2011.766. - DOI - PubMed
-
- Jacobs I.J., Menon U., Ryan A., Gentry-Maharaj A., Burnell M., Kalsi J.K., Amso N.N., Apostolidou S., Benjamin E., Cruickshank D., et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): A randomised controlled trial. Lancet. 2016;387:945–956. doi: 10.1016/S0140-6736(15)01224-6. - DOI - PMC - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous